Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib
{{output}}
Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class... ...
